Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Holdings Inc. is experiencing an upward trend in research and development (R&D) expenditures, with R&D expenses increasing by 21% year over year to $14.0 million and projected to grow by 36% to $58.2 million in 2025, indicating a strong commitment to innovation and product development. The company's General and Administrative (SG&A) expenses have also risen, reflecting ongoing investments in operational capabilities, with a year-over-year increase of 12% to $26.9 million. The positive outlook is further supported by the strategic focus on risk-reward sharing partnerships with medical device companies, positioning the company to potentially enhance market penetration and sales of its high-impact product candidates, including AVIM Therapy and Virtue SAB.

Bears say

Orchestra BioMed Holdings Inc. has consistently experienced operating losses since its inception, reflecting its challenges as a development-stage company. The ongoing financial deficits indicate that the company may struggle to achieve sustainable profitability in the future. With a persistent track record of losses, there is growing concern about the viability of its business model and the company's ability to generate positive financial outcomes.

OBIO has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 4 analysts, OBIO has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.